SecBot SecBot
SECBOTREPLAY Home › Report › AZN

AZN · The Fifth Circuit affirmed Louisiana's Act 358, which prohibits drug…

ASTRAZENECA PLC · COURT-RULING filed Jul 5, 2026 at 20:00 ET

At the news

BEARISHIMPACT 5/10

COURT-RULING filed Jul 5, 2026 at 20:00 ET

The Fifth Circuit affirmed Louisiana's Act 358, which prohibits drug manufacturers from restricting 340B discounted drug delivery to contract pharmacies. AstraZeneca lost its challenge on preemption and Contracts Clause grounds. The ruling is a modest regulatory setback, potentially increasing the volume of 340B discounted sales, but the financial impact is unquantified and likely small relative to AZN's $589B market cap.

  • Fifth Circuit affirmed summary judgment for Louisiana, rejecting AstraZeneca's preemption and Contracts Clause challenges to Act 358
  • Act 358 bars manufacturers from interfering with 340B drug delivery to contract pharmacies
  • Ruling aligns with prior Fifth Circuit precedent in AbbVie v. Fitch regarding Mississippi's similar law
  • No damages awarded; no financial impact quantified in the ruling

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access